Comparison of Calcitonin and Pamidronate Treatments in Children with Osteogenesis Imperfecta

Purpose: The main objective of this study was to compare the treatments of calcitonin and pamidronate by clinical, biochemical, and radiological findings in children with osteogenesis imperfecta and evaluate the efficiency of pamidronate treatment. Patients and methods: A total of 12 patients, aged 41±38 (1-120) months were studied. Group 1 was consisted of six patients who had received intranasal calcitonin at a dosage of 4-6 U/kg three times a week before switching to pamidronate treatment. Group 2 was also consisted of six patients who had received only pamidronate infusion at a dosage of 0.5-2 mg/kg every two months. Results: Annual fracture rates decreased from 2.72 ± 0.80 to 0.40 ± 0.70 (p

[1]  A. Hoischen,et al.  Exome sequencing identifies truncating mutations in human SERPINF1 in autosomal-recessive osteogenesis imperfecta. , 2011, American journal of human genetics.

[2]  P. Lapunzina,et al.  Identification of a frameshift mutation in Osterix in a patient with recessive osteogenesis imperfecta. , 2010, American journal of human genetics.

[3]  P. Byers,et al.  Mutations in the gene encoding the RER protein FKBP65 cause autosomal-recessive osteogenesis imperfecta. , 2010, American journal of human genetics.

[4]  C. Rotimi,et al.  Lack of cyclophilin B in osteogenesis imperfecta with normal collagen folding. , 2010, The New England journal of medicine.

[5]  P. Byers,et al.  Homozygosity for a missense mutation in SERPINH1, which encodes the collagen chaperone protein HSP47, results in severe recessive osteogenesis imperfecta. , 2010, American journal of human genetics.

[6]  G. Pals,et al.  PPIB mutations cause severe osteogenesis imperfecta. , 2009, American journal of human genetics.

[7]  C. Tifft,et al.  Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta , 2007, Nature Genetics.

[8]  J. Mulvihill,et al.  Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta. , 2006, The New England journal of medicine.

[9]  F. Glorieux,et al.  CRTAP Is Required for Prolyl 3- Hydroxylation and Mutations Cause Recessive Osteogenesis Imperfecta , 2006, Cell.

[10]  T. Köse,et al.  Low-dose intravenous pamidronate treatment in osteogenesis imperfecta. , 2006, The Turkish journal of pediatrics.

[11]  J. Troendle,et al.  Controlled Trial of Pamidronate in Children With Types III and IV Osteogenesis Imperfecta Confirms Vertebral Gains but Not Short‐Term Functional Improvement , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[12]  Marni J. Falk,et al.  Intravenous bisphosphonate therapy in children with osteogenesis imperfecta. , 2003, Pediatrics.

[13]  R. Lindsay.  Modeling the benefits of pamidronate in children with osteogenesis imperfecta. , 2002, The Journal of clinical investigation.

[14]  F. Glorieux,et al.  The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. , 2002, The Journal of clinical investigation.

[15]  S. Söderhäll,et al.  Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta , 2002, Archives of disease in childhood.

[16]  F. Glorieux,et al.  Osteogenesis Imperfecta Type VI: A Form of Brittle Bone Disease with a Mineralization Defect , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  S. Vasikaran.  Bisphosphonates: an overview with special reference to alendronate , 2001, Annals of clinical biochemistry.

[18]  Y. Lee,et al.  Cyclic pamidronate infusion improves bone mineralisation and reduces fracture incidence in osteogenesis imperfecta , 2001, European Journal of Pediatrics.

[19]  Mehmet Satar,et al.  Osteogenezis imperfekta lı 15 hastanın değerlendirilmesi , 2001 .

[20]  F. Glorieux.  Bisphosphonate therapy for severe osteogenesis imperfecta. , 2000, Journal of pediatric endocrinology & metabolism : JPEM.

[21]  F. Glorieux,et al.  Type V Osteogenesis Imperfecta: A New Form of Brittle Bone Disease , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[22]  F. Glorieux,et al.  Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. , 1998, The New England journal of medicine.

[23]  B. Bembi,et al.  Intravenous pamidronate treatment in osteogenesis imperfecta. , 1997, The Journal of pediatrics.

[24]  T. Moriwake,et al.  Recent progress in diagnosis and treatment of osteogenesis imperfecta , 1997, Acta paediatrica Japonica : Overseas edition.

[25]  S. Papapoulos,et al.  Long‐Term Effects of Bisphosphonates on the Growing Skeleton: Studies of Young Patients with Severe Osteoporosis , 1997, Medicine.

[26]  Y. Nishi,et al.  Effect of long-term calcitonin therapy by injection and nasal spray on the incidence of fractures in osteogenesis imperfecta. , 1992, The Journal of pediatrics.

[27]  M. Monteiro,et al.  Effects of Synthetic Salmon Calcitonin Therapy in Children with Osteogenesis Imperfecta , 1989, The Journal of international medical research.

[28]  U. Pedersen,et al.  Lack of effects of human calcitonin in osteogenesis imperfecta. , 1985, Acta orthopaedica Scandinavica.

[29]  M. Rízzí,et al.  [Osteogenesis imperfecta and calcitonin. Considerations on 10 years of clinical experimentation]. , 1983, Archivio per le scienze mediche.

[30]  S. Yasumura,et al.  Therapy of osteogenesis imperfecta with synthetic salmon calcitonin. , 1979, The Journal of pediatrics.

[31]  D. Sillence,et al.  Genetic heterogeneity in osteogenesis imperfecta. , 1979, Journal of medical genetics.

[32]  J. Shapiro,et al.  Calcitonin therapy of children with osteogenesis imperfecta. , 1977, The Journal of pediatrics.

[33]  G. Pals,et al.  Classification of Osteogenesis Imperfecta revisited. , 2010, European journal of medical genetics.

[34]  S. Salehpour,et al.  Cyclic Pamidronate Therapy in Children with Osteogenesis Imperfecta , 2010, Journal of pediatric endocrinology & metabolism : JPEM.

[35]  N. Yordam,,et al.  Cyclic Pamidronate Therapy in Children with Osteogenesis Imperfecta: Results of Treatment and Follow-up After Discontinuation , 2008, Journal of pediatric endocrinology & metabolism : JPEM.

[36]  M. Zacharin,et al.  Pamidronate Treatment of Osteogenesis Imperfecta - Lack of Correlation Between Clinical Severity, Age at Onset of Treatment, Predicted Collagen Mutation and Treatment Response , 2002, Journal of pediatric endocrinology & metabolism : JPEM.

[37]  M. Villaronga,et al.  Efficacy of Low Dose Schedule Pamidronate Infusion in Children with Osteogenesis Imperfecta , 2001, Journal of pediatric endocrinology & metabolism : JPEM.

[38]  F. Glorieux.  The use of bisphosphonates in children with osteogenesis imperfecta. , 2001, Journal of pediatric endocrinology & metabolism : JPEM.

[39]  K. Cariappa,et al.  Osteogenesis imperfecta--a case report. , 1985, Journal of the Indian Dental Association.

[40]  P. Byers,et al.  Osteogenesis imperfecta: update and perspective. , 1984, American journal of medical genetics.